Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies

被引：0
|
作者：
Deprimo, Samuel E.
Toner, Guy
Mitchell, Paul
De Boer, Richard
Gibbs, Peter
Hicks, Rodney
McArthur, Grant
Brega, Nicoletta
McCarthy, Timothy
Bello, Carlo
机构：
[1] Pfizer Global R&D, La Jolla, CA USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Austin Hosp, Melbourne, Vic, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Pfizer Srl, Milan, Italy
[6] Pfizer Inc, Groton, CT 06340 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Population pharmacokinetics (PIK) of sunitinib malate (SU11248) and its primary metabolite (SU12662) in oncology patients and healthy volunteers.
    Houk, B
    Garrett, M
    Bello, C
    Poland, B
    Wagg, J
    Gao, YY
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9074S - 9075S
  • [12] Preliminary results of an expanded-access trial of sunitinib malate (SU11248) for the treatment of patients with refractory metastatic renal cell carcinoma (MRCC)
    Bukowski, Ronald M.
    Szczylik, Cezary
    Porta, Camillo
    Bodrogi, Istvan
    Eisen, Timothy
    Oudard, Stephane
    Bjarnason, Georg
    Hawkins, Robert
    Wilner, Keith
    Chen, Isan
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [13] Results of a phase II study with sunitinilb malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)
    Kulka, M.
    Lenz, H.
    Meropol, N.
    Posey, J.
    Picus, J.
    Ryan, D.
    Bergsland, E.
    Stuart, K.
    Baum, C.
    Fuchs, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 204 - 204
  • [14] Circulating endothelial cells and monocytes as markers of sunitinib malate (SU11248) activity in patients with imatinib mesylate-resistant GIST
    Norden-Zfoni, A.
    Manola, J.
    Desai, J.
    Morgan, J.
    Bello, C.
    DePrimo, S.
    Shalinsky, D.
    Baum, C.
    Demetri, G.
    Heymach, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 423 - 423
  • [15] Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).
    Rini, B. I.
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Bukowski, R. M.
    Sosman, J. A.
    Stadler, W. M.
    Margolin, K.
    Hutson, T. E.
    Baum, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 222S - 222S
  • [16] Phase III study of sunitinib malate (SU11248) versus interferon-α as first-line treatment in patients with metastatic renal cell carcinoma
    Reddy, Kesava
    CLINICAL GENITOURINARY CANCER, 2006, 5 (01) : 23 - 25
  • [17] SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model
    Bauerschlag, D. O.
    Schem, C.
    Tiwari, S.
    Meinhold-Heerlein, I.
    Mundhenke, C.
    Weigel, M.
    Egberts, J. H.
    Kalthoff, H.
    Jonat, W.
    Maass, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [18] A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
    Houk, Brett E.
    Bello, Carlo L.
    Kang, Dongwoo
    Amantea, Michael
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2497 - 2506
  • [19] Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
    Rini, Brian I.
    George, Daniel J.
    Michaelson, M. Dror
    Rosenberg, Jonathan E.
    Bukowski, Ronald M.
    Sosman, Jeffrey A.
    Stadler, Walter M.
    Margolin, Kim
    Hutson, Thomas E.
    Baum, Charles M.
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [20] SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 172 - 172
12345